Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Systemic Lupus Erythematosus: HELP
Articles by Radboud J. E. M. Dolhain
Based on 3 articles published since 2008
||||

Between 2008 and 2019, R. Dolhain wrote the following 3 articles about Lupus Erythematosus, Systemic.
 
+ Citations + Abstracts
1 Review State of the art: Reproduction and pregnancy in rheumatic diseases. 2015

Østensen, Monika / Andreoli, Laura / Brucato, Antonio / Cetin, Irene / Chambers, Christina / Clowse, Megan E B / Costedoat-Chalumeau, Nathalie / Cutolo, Maurizio / Dolhain, Radboud / Fenstad, M H / Förger, Frauke / Wahren-Herlenius, Marie / Ruiz-Irastorza, Guillermo / Koksvik, Hege / Nelson-Piercy, Catherine / Shoenfeld, Yehuda / Tincani, Angela / Villiger, Peter M / Wallenius, Marianne / von Wolff, Michael. ·National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, St. Olavs Hospital, University Hospital of Trondheim, Norway. Electronic address: monika.ostensen@gmail.com. · Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Italy. · Department of Internal Medicine, Ospedale papa Giovanni XXIII Bergamo, Italy. · Department of Mother and Child, Hospital Luigi Sacco, University of Milano, Italy. · Department of Pediatrics, University of California San Diego, La Jolla, CA 92093-0828, USA. · Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, USA. · Université Paris-Descartes, Paris, France; AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, Service de médecine interne, Paris, France. · Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy. · Department of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. · Department of Immunology and Transfusion Medicine, St. Olavs Hospital, Trondheim, Norway. · Department of Rheumatology and Clinical Immunology/Allergology, University Hospital of Bern, CH-3010 Bern, Switzerland. · Department of Medicine, Centre for Molecular Medicine, Karolinska Universitetssjukhuset, Stockholm, Sweden. · Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain. · National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, St. Olavs Hospital, University Hospital of Trondheim, Norway. · Women's Health Academic Centre, St Thomas' Hospital, London, UK. · Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel. · Department of Rheumatology and Clinical Immunology, Ospedale Civile and University of Brescia, Brescia, Italy. · Department of Rheumatology and Clinical Immunology/Allergology, University Hospital of Bern, Bern, Switzerland. · National Service for Pregnancy and Rheumatic Diseases, Department of Rheumatology, Trondheim University Hospital, Trondheim, Norway; Dept of Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. · University Women's Hospital, Division of Gynaecological Endocrinology and Reproductive Medicine, University of Berne, Berne, Switzerland. ·Autoimmun Rev · Pubmed #25555818.

ABSTRACT: Throughout the last decade, increasing awareness has been raised on issues related to reproduction in rheumatic diseases including basic research to clarify the important role of estrogens in the etiology and pathophysiology of immune/inflammatory diseases. Sub- or infertility is a heterogeneous condition that can be related to immunological mechanisms, to pregnancy loss, to disease burden, to therapy, and to choices in regard to family size. Progress in reproductive medicine has made it possible for more patients with rheumatic disease to have children. Active disease in women with rheumatoid arthritis (RA) affects their children's birth weight and may have long-term effects on their future health status. Pregnancy complications as preeclampsia and intrauterine growth restriction are still increased in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), however, biomarkers can monitor adverse events, and several new therapies may improve outcomes. Pregnancies in women with APS remain a challenge, and better therapies for the obstetric APS are needed. New prospective studies indicate improved outcomes for pregnancies in women with rare diseases like systemic sclerosis and vasculitis. TNF inhibitors hold promise for maintaining remission in rheumatological patients and may be continued at least in the first half of pregnancy. Pre-conceptional counseling and interdisciplinary management of pregnancies are essential for ensuring optimal pregnancy outcomes.

2 Article T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus? 2014

Brkic, Zana / Corneth, Odilia B J / van Helden-Meeuwsen, Cornelia G / Dolhain, Radboud J E M / Maria, Naomi I / Paulissen, Sandra M J / Davelaar, Nadine / van Hamburg, Jan Piet / van Daele, Paul L / Dalm, Virgil A / van Hagen, P Martin / Hazes, Johanna M W / Versnel, Marjan A / Lubberts, Erik. · ·Arthritis Res Ther · Pubmed #24598455.

ABSTRACT: INTRODUCTION: A hallmark of systemic autoimmune diseases like systemic lupus erythematosus (SLE) is the increased expression of interferon (IFN) type I inducible genes, so-called IFN type I signature. Recently, T-helper 17 subset (Th17 cells), which produces IL-17A, IL-17F, IL-21, and IL-22, has been implicated in SLE. As CCR6 enriches for Th17 cells, we used this approach to investigate whether CCR6⁺ memory T-helper cells producing IL-17A, IL-17F, IL-21, and/or IL-22 are increased in SLE patients and whether this increase is related to the presence of IFN type I signature. METHODS: In total, 25 SLE patients and 15 healthy controls (HCs) were included. SLE patients were divided into IFN type I signature-positive (IFN⁺) (n = 16) and negative (IFN⁻) (n = 9) patients, as assessed by mRNA expression of IFN-inducible genes (IFIGs) in monocytes. Expression of IL-17A, IL-17F, IL-21, and IL-22 by CD4⁺CD45RO⁺CCR6⁺ T cells (CCR6⁺ cells) was measured with flow cytometry and compared between IFN⁺, IFN⁻ patients and HCs. RESULTS: Increased percentages of IL-17A and IL-17A/IL-17F double-producing CCR6⁺ cells were observed in IFN⁺ patients compared with IFN⁻ patients and HCs. IL-17A and IL-17F expression within CCR6⁺ cells correlated significantly with IFIG expression. In addition, we found significant correlation between B-cell activating factor of the tumor necrosis family (BAFF)-a factor strongly correlating with IFN type I - and IL-21 producing CCR6⁺ cells. CONCLUSIONS: We show for the first time higher percentages of IL-17A and IL-17A/IL-17F double-producing CCR6⁺ memory T-helper cells in IFN⁺ SLE patients, supporting the hypothesis that IFN type I co-acts with Th17 cytokines in SLE pathogenesis.

3 Article Complicated systemic lupus erythematosus pancreatitis: pseudocyst, pseudoaneurysm, but real bleeding. 2011

Hoorn, E J / Flink, H J / Kuipers, E J / Poley, J-W / Mensink, P B F / Dolhain, R J E M. ·Departments of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. ejhoorn@gmail.com ·Lupus · Pubmed #20956462.

ABSTRACT: We report the case of a 25-year-old patient with systemic lupus erythematosus (SLE) pancreatitis which was complicated by pseudocyst and pseudoaneurysm formation. The pseudoaneurysm progressed to intra-abdominal bleeding requiring endovascular coil embolization of the gastroduodenal artery. The pseudocyst and hematoma formed two large abdominal fluid collections causing symptoms due to a mass effect. These fluid collections were treated conservatively, while active SLE was treated with steroids, azathioprine, and immunoglobulins. She finally made a full recovery. To the best of our knowledge, this is the first report of a bleeding pseudoaneurysm complicating SLE pancreatitis. Although anecdotal, this case may serve as a useful example of the possible complications of SLE pancreatitis, including considerations on optimal management.